IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian CancerGlobeNewsWire • 02/27/23
IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating LossesGlobeNewsWire • 01/12/23
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute's Vaccine & Immunotherapy Center to Research IMUNON's PLACCINE Vaccine PlatformGlobeNewsWire • 01/05/23
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive AdvantagesGlobeNewsWire • 12/01/22
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022GlobeNewsWire • 11/22/22
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/22
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON's PLACCINE Plasmid DNA with Acuitas' Lipid Nanoparticle Delivery SystemGlobeNewsWire • 11/10/22
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022GlobeNewsWire • 11/07/22